Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Spectrum Pharmaceuticals Inc (NASDAQ:SPPI)

4.00
Delayed Data
As of Dec 02
 -0.10 / -2.44%
Today’s Change
3.21
Today|||52-Week Range
7.74
-33.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$322.2M

Company Description

Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.

Contact Information

Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue
Henderson Nevada 89052
P:(702) 835-6300
Investor Relations:

Employees

Shareholders

Other institutional42.07%
Individual stakeholders4.98%
Mutual fund holders35.48%

Top Executives

Rajesh C. ShrotriyaChairman & Chief Executive Officer
Joseph G. TurgeonPresident & Chief Operating Officer
Kurt A. GustafsonChief Financial Officer & Executive Vice President
Thomas J. RigaChief Commercial Officer & Senior Vice President
Robert FralinVice President-National Accounts & Trade